Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the听2025 SNO/ASCO CNS Metastases Conference
Plus Therapeutics (NASDAQ:PSTV) presented positive data from their CNSide庐 Cerebrospinal Fluid (CSF) Assay Platform at the 2025 SNO/ASCO CNS Metastases Conference. The retrospective analysis, involving 613 CNSide assays from 218 patients across 5 institutions, demonstrated significant capabilities in detecting and monitoring leptomeningeal metastases (LM).
Key findings include 67% detection rate of CSF tumor cells, with notable observations of immunocytochemistry and FISH probe detection changes in patients with multiple CSF draws. The platform showed 2.8 times higher diagnostic sensitivity compared to standard CSF cytology and influenced clinical management decisions in over 90% of LM cases.
Plus Therapeutics (NASDAQ:PSTV) ha presentato dati positivi dalla sua piattaforma CNSide庐 per l'analisi del liquido cerebrospinale (CSF) alla conferenza 2025 SNO/ASCO sulle metastasi del SNC. L'analisi retrospettiva, che ha coinvolto 613 saggi CNSide su 218 pazienti in 5 istituti, ha mostrato capacit脿 significative nel rilevare e monitorare le metastasi leptomeningee (LM).
I risultati principali includono un tasso di rilevazione del 67% di cellule tumorali nel CSF, con osservazioni rilevanti di variazioni nella rilevazione tramite immunocitochimica e sonde FISH in pazienti con prelievi CSF multipli. La piattaforma ha evidenziato una sensibilit脿 diagnostica 2,8 volte superiore rispetto alla citologia tradizionale del CSF e ha influenzato le decisioni di gestione clinica in oltre il 90% dei casi di LM.
Plus Therapeutics (NASDAQ:PSTV) present贸 datos positivos de su plataforma CNSide庐 para ensayos en l铆quido cefalorraqu铆deo (CSF) en la conferencia 2025 SNO/ASCO sobre met谩stasis del SNC. El an谩lisis retrospectivo, que incluy贸 613 ensayos CNSide de 218 pacientes en 5 instituciones, demostr贸 una capacidad notable para detectar y monitorizar las met谩stasis leptomen铆ngeas (LM).
Los hallazgos clave incluyen una tasa de detecci贸n del 67% de c茅lulas tumorales en el CSF, con observaciones destacadas de cambios en la detecci贸n mediante inmunocitoqu铆mica y sondas FISH en pacientes con m煤ltiples extracciones de CSF. La plataforma mostr贸 una sensibilidad diagn贸stica 2,8 veces mayor que la citolog铆a est谩ndar del CSF e influy贸 en las decisiones de manejo cl铆nico en m谩s del 90% de los casos de LM.
Plus Therapeutics (NASDAQ:PSTV)電� 2025雲� SNO/ASCO 欷戩稊鞁犼步瓿� 鞝勳澊 頃欗殞鞐愳劀 鞛愳偓鞚� CNSide庐 雵岇矙靾橃暋(CSF) 攵勳劃 頂岆灚韽检潣 旮嶌爼鞝侅澑 雿办澊韯半ゼ 氚滍憸頄堨姷雼堧嫟. 5臧� 旮瓣磤鞚� 218氇� 頇橃瀽鞐愳劀 鞁滍枆霅� 613瓯挫潣 CNSide 瓴�靷�毳� 韽暔頃� 頉勴枼鞝� 攵勳劃鞚� 雵岇矙靾橂 鞝勳澊(LM)鞚� 瓴�於� 氚� 氇媹韯半鞐愳劀 鞚橂 鞛堧姅 靹彪姤鞚� 氤挫榾鞀惦媹雼�.
頃奠嫭 瓴瓣臣搿滊姅 CSF 雮� 膦呾枒靹疙彫鞚� 67% 瓴�於滊瓿� 雼ろ殞 CSF 毂勳法 頇橃瀽鞐愳劀 氅挫棴靹疙彫頇旐暀 瓴�靷� 氚� FISH 韮愳龚 瓴�於滌潣 氤�頇旉皜 甏�彀半悳 鞝愳澊 韽暔霅╇媹雼�. 鞚� 頂岆灚韽检潃 響滌 CSF 靹疙彫瓴�靷檧 牍勱祼頃橃棳 歆勲嫧 氙缄皭霃勱皜 2.8氚� 雴掛晿鞙茧┌, LM 靷鞚� 90% 鞚挫儊鞐愳劀 鞛勳儊鞝� 旃橂 瓴办爼鞐� 鞓來枼鞚� 氙胳长鞀惦媹雼�.
Plus Therapeutics (NASDAQ:PSTV) a pr茅sent茅 des donn茅es positives de sa plateforme d'analyse CNSide庐 du liquide c茅r茅bro-spinal (LCS) lors de la conf茅rence SNO/ASCO 2025 sur les m茅tastases du SNC. L'analyse r茅trospective, portant sur 613 tests CNSide issus de 218 patients dans 5 茅tablissements, a montr茅 une capacit茅 importante 脿 d茅tecter et surveiller les m茅tastases leptomening茅es (ML).
Les r茅sultats cl茅s incluent un taux de d茅tection de 67% des cellules tumorales dans le LCS, avec des observations notables de modifications de la d茅tection par immunocytochimie et sondes FISH chez des patients ayant subi plusieurs ponctions de LCS. La plateforme a d茅montr茅 une sensibilit茅 diagnostique 2,8 fois sup茅rieure 脿 la cytologie standard du LCS et a influenc茅 les d茅cisions de prise en charge clinique dans plus de 90% des cas de ML.
Plus Therapeutics (NASDAQ:PSTV) stellte positive Daten seiner CNSide庐-Liquor(CSF)-Assayplattform auf der SNO/ASCO-Konferenz 2025 zu ZNS-Metastasen vor. Die retrospektive Analyse, die 613 CNSide-Assays von 218 Patienten an 5 Einrichtungen umfasste, zeigte eine deutliche F盲higkeit zur Erkennung und 脺berwachung leptomeningealer Metastasen (LM).
Wesentliche Ergebnisse sind eine Detektionsrate von 67% f眉r Tumorzellen im CSF sowie bemerkenswerte Ver盲nderungen bei der Nachweisbarkeit mittels Immunzytochemie und FISH-Sonden bei Patienten mit mehreren CSF-Entnahmen. Die Plattform erzielte eine 2,8-fach h枚here diagnostische Sensitivit盲t gegen眉ber der Standard-CSF-Zytologie und beeinflusste die klinische Entscheidungsfindung in 眉ber 90% der LM-F盲lle.
- None.
- None.
Insights
Plus Therapeutics' CNSide assay shows promising ability to detect and monitor leptomeningeal metastases, potentially transforming treatment approaches.
The data presented at the SNO/ASCO CNS Metastases Conference represents a significant advancement in the management of leptomeningeal metastases (LM), a notoriously difficult-to-treat form of cancer spread. The CNSide platform demonstrated 67% detection rate of CSF tumor cells across 613 assays, substantially outperforming standard CSF cytology with 2.8 times greater diagnostic sensitivity.
What's particularly valuable is the platform's ability to monitor changes in tumor biology over time. The study showed that 20% of patients experienced shifts in immunocytochemistry detection and a remarkable 88% showed changes in FISH probe detection across multiple CSF draws. This capability to detect "oncogenic flips" provides clinicians with crucial real-time information about evolving tumor characteristics.
The clinical implications are substantial. The FORESEE study demonstrated that CNSide influenced clinical management decisions in over 90% of LM cases, potentially allowing physicians to adapt treatment strategies as tumor biology changes. For Plus Therapeutics, this strengthens their position in the CNS cancer space by complementing their radiotherapeutic pipeline with advanced diagnostic capabilities.
This technology addresses a critical unmet need in neuro-oncology. LM diagnosis has historically relied on less sensitive methods, often leading to delayed treatment initiation and suboptimal outcomes. By providing both enhanced detection and molecular characterization of CSF tumor cells, CNSide could enable earlier intervention and more personalized treatment approaches for patients with these challenging CNS malignancies.
CNSide庐 can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations
CNSide庐 may catalyze LM treatment initiation, allow physicians to adapt treatment with real time shifts in tumor biology, and enable personalized cancer therapy
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 听(狈补蝉诲补辩:听) (鈥淧lus鈥� or the 鈥淐ompany鈥�), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced positive data from a retrospective analysis of the CNSide Cerebrospinal Fluid (CSF) Assay Platform at the 2025 Society for Neuro-Oncology (SNO)/American Society of Clinical Oncology (ASCO) CNS Metastases Conference in Baltimore, Maryland.
The presentation, titled 鈥淭he Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease (LMD): Longitudinal Detection in Cerebrospinal Fluid Tumor Cells (CSF-TCs) Reveals Implications for Differential Treatment of the LMD Tumor,鈥� was a retrospective, multi-center analysis of 613 CNSide assays ordered by 19 physicians from 5 institutions at 2 health systems for 218 individual patients.
Data Demonstrated:
- CSF tumor cells detected in
67% (412/613) patients using CNSide; - 66 patients underwent 2 or more CSF draws; 24 patients underwent 5 or more;
20% (13/66) of patients were found to have a flip in immunocytochemistry (ICC) detection; and88% (58/66) of patients were found to have a flip in FISH probe detection.
鈥淭he CNSide CSF Assay Platform can be used to detect gene amplification on CSF tumor cells of patients with LM and, therefore, may provide therapeutic insights to specifically target the LM tumor,鈥� said Priya U. Kumthekar, M.D.,听鈥淔urther, longitudinal CSF tumor cell analysis using CNSide may provide insights to modify treatment of the LM tumor over time.鈥�
The data builds upon previously announced results, 鈥淐SF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker Assessment Helps in Clinical Management of Breast Cancer and Non-Small Cell Lung Cancer Patients Having Leptomeningeal Disease,鈥� from the prospective study, which was also presented by Dr. Kumthekar, principal investigator. The study met key primary and secondary endpoints and showed that the CNSide CSF Assay platform influenced clinical management decisions in over
About CNSide Diagnostic, LLC听
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide庐, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide庐听CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases.
About Leptomeningeal Metastases
Leptomeningeal metastases (LM) are a rare but severe complication of advanced cancer, affecting the fluid-lined structures of the central nervous system. LM occurs in approximately
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit .
Forward-Looking Statements
This press release contains statements that may be deemed 鈥渇orward-looking statements鈥� within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as 鈥渆xpect,鈥� 鈥減otential,鈥� 鈥渁nticipating,鈥� 鈥減lanning鈥� and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.
These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company鈥檚 future performance, including the next steps in developing the Company鈥檚 product candidates.
Investor Contact
CORE IR
听
FAQ
What were the key findings of Plus Therapeutics' (PSTV) CNSide platform study presented at SNO/ASCO 2025?
How many patients were included in Plus Therapeutics' CNSide platform analysis?
What types of cancer were most analyzed in the PSTV CNSide study?
How does Plus Therapeutics' CNSide platform help in treating leptomeningeal metastases?
What was the significance of the 'oncogenic flip' detected by PSTV's CNSide platform?
